Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Milberg, Oleg [1 ]
Chiu, Joannellyn [1 ]
Hazra, Anasuya [1 ]
Upadhyay, Sameer [1 ]
Kroog, Glenn S. [1 ]
Lorenc, Karen Rodriguez [1 ]
Davis, John D. [1 ]
Dicioccio, A. Thomas [1 ]
Harnisch, Lutz O. [1 ]
Chittenden, Jason [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200109
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7056 / 7057
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF SELINEXOR FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS
    Abushanab, D.
    Mraiche, F.
    Al-Badriyeh, D.
    VALUE IN HEALTH, 2021, 24 : S22 - S22
  • [32] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
    Shafei, Laila
    Bashir, Shaima
    Chan, Esther W.
    Abushanab, Dina
    Hamad, Anas
    Al-Badriyeh, Daoud
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [33] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (04) : 772 - 778
  • [34] Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
    Xu, Xu Steven
    Dimopoulos, Meletios A.
    Sonneveld, Pieter
    Ho, P. Joy
    Belch, Andrew
    Leiba, Merav
    Capra, Marcelo
    Gomez, David
    Medvedova, Eva
    Iida, Shinsuke
    Min, Chang-Ki
    Schecter, Jordan
    Jansson, Richard
    Zhang, Liping
    Sun, Yu-Nien
    Clemens, Pamela L.
    ADVANCES IN THERAPY, 2018, 35 (11) : 1859 - 1872
  • [35] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Berenson, James R.
    Silagan, Noemi
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Forouzan, Eli
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Boccia, Ralph V.
    Yang, Honghao Hank
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2020, 136
  • [36] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
    Gao, Xiaohui
    Zeng, Hui
    Zhao, Xiaoyan
    Wu, Haibing
    Yan, Minchao
    Li, Yuan
    Zhang, Gang
    Sun, Fei
    BMC CANCER, 2023, 23 (01)
  • [37] Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
    Jing-di Liu
    Chun-yan Sun
    Liang Tang
    Ying-ying Wu
    Qing-yun Wang
    Bei Hu
    Yu Hu
    Scientific Reports, 6
  • [38] LENALIDOMIDE COMBINED WITH LIPOSOMAL DOXORUBICIN AND LOW DOSE DEXAMETHASONE (RDD) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: SAFETY AND EFFICACY
    Pavone, V.
    Mele, A.
    De Risi, C.
    Rossini, B.
    Carlino, D.
    Sibilla, S.
    De Francesco, R.
    Greco, G.
    Fina, M.
    Ferrara, P.
    Morciano, M.
    Ostuni, A.
    Pavone, V.
    HAEMATOLOGICA, 2012, 97 : 602 - 603
  • [39] Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
    Liu, Jing-di
    Sun, Chun-yan
    Tang, Liang
    Wu, Ying-ying
    Wang, Qing-yun
    Hu, Bei
    Hu, Yu
    SCIENTIFIC REPORTS, 2016, 6
  • [40] Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Takafumi Ide
    Mayu Osawa
    Kinjal Sanghavi
    Heather E. Vezina
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 129 - 140
12345